Analyst Bursts Edwards’ Bubble On PARTNER Percutaneous Valve Trial
This article was originally published in The Gray Sheet
Executive Summary
An analyst raised doubts last week about Edwards Lifesciences' ability to gain approval for all studied indications in its closely watched U.S. trial for the Sapien percutaneous aortic valve